| dc.creator |
Erik Alsegård |
|
| dc.date |
2004 |
|
| dc.date.accessioned |
2013-05-30T13:57:47Z |
|
| dc.date.available |
2013-05-30T13:57:47Z |
|
| dc.date.issued |
2013-05-30 |
|
| dc.identifier |
http://www.law.ed.ac.uk/ahrb/script-ed/docs/doha.asp |
|
| dc.identifier |
http://www.doaj.org/doaj?func=openurl&genre=article&issn=17442567&date=2004&volume=1&issue=1&spage=12 |
|
| dc.identifier.uri |
http://koha.mediu.edu.my:8181/jspui/handle/123456789/5982 |
|
| dc.description |
The purpose of this article is to analyse how developments after the Doha Declaration went wrong; how developing countries can best be helped by IPR legislation; and whether such help can be achieved without taking away the incentives for industry to develop medicines. It is submitted that a legal framework maintaining the global protection of IPRs is needed, especially in developed countries, but that such a framework must allow for compulsory licensing in separate, regional generic markets , and must further create effective barriers for (re-)import into other countries than those targeted by the compulsory licence. This proposal would create a large market currently unused, in which pharmaceuticals could be produced and sold more cheaply, while protecting developed countries from importation of generic drugs. This way, compulsory licensing should work as a tool to promote innovation whilst also protecting public health globally. |
|
| dc.publisher |
AHRB Research Centre for Studies in Intellectual Property and Technology Law |
|
| dc.source |
SCRIPT-ed |
|
| dc.subject |
Doha |
|
| dc.subject |
acces to medicines |
|
| dc.subject |
patents |
|
| dc.subject |
pharmaceuticals |
|
| dc.title |
Global pharmaceutical patents after the Doha Declaration What lies in the future? |
|